Pharma Focus Asia
Eppendorf Bioprocess Solutions

Jellagen ® Ltd announces a collaboration with the Mayo Clinic

Wednesday, September 30, 2020

Jellagen® Limited, a marine biotechnology company producing high-value collagen derived from jellyfish, has entered into a licensing agreement to grant exclusive patent rights for the development to the Mayo Clinic treatment of vocal cord paralysis.

Vocal cord paralysis (VCP) is an injury to one or both of the recurrent laryngeal nerves (RLN) that control most of the muscles in the larynx, resulting in paralysis of the vocal cord muscles, which in turn can result in l airway obstruction, dyspnoea, vocal changes, etc. Vocal cord paralysis is caused by the side effects of surgery, trauma, cancer, and more.

The original text of this announcement, written in the source language, is the authentic official version. Translations are offered solely for the convenience of the reader and must refer to the original text, which is the only legally valid text.

Adam Watts, Digital Marketing Manager at Jellagen
Tel .: +44 (0) 3333 583 299

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACPHI Korea 2023Bora Pharmaceutical - A robust approach to analytical testing is essentialSelangor International Expo MEDIC 2023TFS - Webinar - DynaSpin™ Single-Use Centrifuge for harvest applicationsMedical Fair Thailand 2023ThermoFisher Scientific - NEW Mobile AppCPHI & PMEC China 20233rd ANNUAL COMPUTER SOFTWARE ASSURANCE 2023Pharma Regulatory Conclave 202320th Anniversary Hospitalog Asia 2023
Charles River Laboratories - Endosafe Compendial LAL Cartridge Technology